Polaryx Therapeutics (PLYX) : 3-week performance

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 11
• Founded by Hahn-Jun Lee in 2014 
• HQ: Paramus, New Jersey
• https://polaryx.com

The company focuses on developing patient-friendly, orally available small molecule therapies (and some gene therapy candidates) for rare pediatric lysosomal storage disorders (LSDs), such as neuronal ceroid lipofuscinosis (e.g., CLN2, CLN3), Krabbe disease, Sandhoff disease, and others.

• Lead Candidate: PLX-200 (a repurposed oral small molecule, e.g., based on gemfibrozil) targets multiple LSDs by promoting lysosome biogenesis, reducing inflammation, and protecting neuronal function.
• Pipeline: Includes PLX-100, PLX-300 (preclinical combinations), and PLX-400 (preclinical gene therapy).

ZIM Integrated Shipping (ZIM) to be acquired by Hapag-Lloyd for $35 per share in $4.2 bln cash deal

 

 

 

 

• Chart the day before, Fri 13 Feb 2026 

 

  

Hapag-Lloyd (OTC: HPGLY) is buying Israeli competitor Zim Integrated Shipping Services for $4.2 billion as the shipping firm looks to bolster its capacity.

Germany-based Hapag-Lloyd said Monday that it signed a deal to buy Zim for $35 a share in cash, a 58% premium to Zim’s closing price of $22.20 on Friday. The total deal price of around $4.2 billion will be funded from cash reserves and external financing of up to $2.5 billion.

The combined business will have a standing capacity of more than 3 million twenty-foot equivalent units, the standard form of measurement in container shipping, and more than 400 vessels. Hapag-Lloyd currently has vessel capacity of 2.5 million TEU and 305 vessels, according to the company’s website.

The deal is expected to be completed by the end of this year, Hapag-Lloyd said. Any deal will require the consent of the state of Israel, Zim shareholders and regulators.

Zim is considered a strategic asset for the Israeli state. As part of the deal, Israel’s special stake in Zim will be transferred to a carved-out container business, which will be owned by Israeli private-equity firm FIMI, Hapag-Lloyd said. The new container line will start with 16 vessels, according to Hapag-Lloyd.

The move comes after Zim appointed an independent board that has spent the last several months conducting a strategic review to assess a range of options, including a sale of the company, capital allocation options and other measures to maximize shareholder value.

Zim recently reported a sharp drop in third-quarter earnings as freight rates tumbled and container volumes slipped, with the company warning that fourth-quarter conditions had weakened.

IPOs this week : Feb 9 - 13, 26 (wk 7)

 IPOs expected to price

• AGI (AGBK), 

• Arko Petroleum (APC), and 

• Clear Street Group (CLRS) are expected to price their IPOs and begin to trade. 

IPO lockup expirations

The IPO lockup period expires for blocks of shares of 

• Bullish (BLSH), 

• Nasus Pharma (NSRX), and 

• Magnitude International (MAGH).

Once Upon a Farm (OFRM) began trading on the NYSE on Fri 6 Feb 26

Once Upon A Farm PBC manufactures baby, toddler and kids nutrition food products. It offers fruits, vegetables and superfood blends that are specifically customized for children. 

• Sector: Consumer Defensive
• Industry: Packaged Foods
• Full Time Employees: 144
• Founded by John M. Foraker, Jennifer Garner, Curtis Cassandra and Ari Raz in 2015 
• Headquartered in Berkeley, California
• https://onceuponafarmorganics.com

Opened at $21 after pricing a 10,997,209 share IPO at $18.00 per share, at the midpoint of the $17-19 expected range at $18/share 

Ticker: OFRM

 

Co-founders: John M. Foraker, Jennifer Garner, Curtis Cassandra and Ari Raz 

2nd day 

 

 

1 week  

AgomAb Therapeutics NV (AGMB) began trading on the Nasdaq on Fri 6 Feb 26

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 57
• Incorporated in 2017 
• Headquartered in Antwerp, Belgium
• https://agomab.com

AgomAb Therapeutics NV opened at $14.70 after pricing a 12.5 mln share IPO at $16.00 per ADS, at the midpoint of the $15-17 expected range

 

SpyGlass Pharma (SGP) began trading on the Nasdaq on Fri 6 Feb 26

SpyGlass Pharma opened at $24 after pricing a 9.375 mln share IPO at $16.00 per share, at the midpoint of the $15-17 expected range

• SpyGlass Pharma (SGP) roared onto the public markets today, as its IPO of 9.375 mln shares priced at the $16 midpoint of its $15-$17 range, opened for trading at $24 (a 50% gain), and is currently trading near $29.
• The company's lead product candidate, the Bimatoprost Drug Pad-IOL System, targets the $13 bln glaucoma market by attaching drug-eluting pads to an intraocular lens implanted during routine cataract surgery, delivering three years of medication to solve the critical issue of patient non-adherence to daily drops.
• While SGP remains pre-revenue with a net loss of $27.3 mln for the first nine months of 2025, its growth strategy relies on leveraging a known drug (bimatoprost) and a standard surgical procedure to pursue a streamlined regulatory pathway.
• Beyond its lead asset, the company is advancing a "Drug Ring System" for standalone procedures, positioning its proprietary platform as a versatile, lifetime solution for chronic eye conditions.
• The enthusiastic investor reception reflects high confidence in a technology that integrates seamlessly into the existing cataract workflow without requiring surgeons to learn complex new techniques.
• Ultimately, the market is pricing in a "de-risked" commercialization path, supported by the company's plan to utilize existing CPT reimbursement codes to align provider economics with improved patient outcomes.
• SpyGlass, based in California, is making drug-device combinations for ocular conditions. One program is a lens implanted during cataract surgery. With the help of attached drug pads, it’s meant to treat glaucoma and ocular hypertension by slowly releasing a medication that lowers eye pressure. The therapy, codenamed BIM-IOL, is currently in two Phase 3 studies that started last month. SpyGlass expects to complete enrollment in 2027.

SpyGlass Pharma is a biopharmaceutical company focused on developing sustained drug delivery systems for chronic eye diseases, particularly glaucoma. Their approach uses a proprietary non-bioerodible platform to deliver medications long-term, often integrated with existing procedures like cataract surgery.Their main drug candidates, based on their pipeline and recent clinical advancements (as of early 2026), are:

• BIM-IOL System (Bimatoprost Drug Pad-Intraocular Lens System): This is their lead product candidate. It involves proprietary non-bioerodible drug pads attached to a monofocal intraocular lens (IOL), implanted during routine cataract surgery. It delivers bimatoprost (a prostaglandin analog) sustained over up to 3 years to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
  • It is in Phase III development, with two registrational trials (SGP-005 and SGP-006) having started randomization in January 2026.
  • Earlier trials (including 36-month first-in-human data) showed positive results, such as ~37% mean IOP reduction and safety comparable to standard cataract surgery.
• BIM-DRS (Bimatoprost Drug Ring System): This is their next-generation sustained-release implant. It is a removable and replaceable ring-shaped device for multi-year drug delivery (also bimatoprost). It targets a broader glaucoma population (including those not undergoing cataract surgery) and enables retreatment for patients previously treated with the BIM-IOL System. It has potential for lifelong disease management.
  • It is earlier in development, with first-in-human studies planned for 2026.

The company's platform is designed to be flexible for other approved medications and conditions (e.g., front/back of the eye diseases), with early/preclinical mentions of potential applications like postoperative steroids, NSAIDs, chronic uveitis, or age-related macular degeneration. However, the primary focus and most advanced candidates center on the bimatoprost-based systems for glaucoma.

OpenAI

OpenAI is not owned by a single entity, but rather operates under a complex hybrid structure. As of late 2025, it is controlled by the non-profit OpenAI Foundation (holding ~26-30%), while Microsoft holds a major stake (approx. 27-49%). Employees and other investors like Thrive Capital and Khosla Ventures hold the remaining equity. 

Key Details on Ownership & Structure:

• Non-Profit Control: The OpenAI Foundation (parent company) governs the for-profit, capped-profit subsidiary (OpenAI LP) to ensure the mission of safe AI development is prioritized over pure profit.

• Microsoft's Role: Microsoft has invested over $13 billion in total. While some reports indicate they hold 49% of the profit-sharing, other 2025 reports indicate a ~27-30% direct equity stake following company restructuring.

• Structure: OpenAI restructured into a for-profit "Group PBC" (Public Benefit Corporation) to allow for greater investment while keeping the non-profit as a majority stakeholder of the company's direction.

• Employee & Investor Ownership: A large portion of the company (roughly 30–47% depending on the report) is held by employees and various venture capital firms. 

Bob's Discount Furniture (BOBS) began trading on the NYSE on Thur 5 Feb 26

Bob's Discount Furniture, Inc. engages in retailing home furnishings in the United States.

The company was formerly known as BDF Holding Corp. and changed its name to Bob's Discount Furniture, Inc. in October 2025. 

• Sector: Consumer Cyclical
• Industry: Specialty Retail
• Founded in 1991 
• HQ in Manchester, Connecticut
• https://www.mybobs.com

Bob's Discount Furniture priced 19.45 mln share IPO at $17.00 per share, at the low end of the $17-19 expected range

 

 CEO Bill Barton of Bob’s Discount Furniture at the New York Stock Exchange on Feb. 5, 2026.

 

Eikon Therapeutics (EIKN) began trading on the Nasdaq on Thur 5 Feb 26

• Sector: HealthcareIndustry: Biotechnology
• Incorporated in 2019 
• HQ in Millbrae, California
• https://www.eikontx.com/

Eikon Therapeutics priced 21,177,600 share IPO (upgraded from 17.7 mln prior) at $18.00 per share, at the high end of the $16-18 expected range

Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024

Ticker: EIKN

At $381 million, Eikon looks set to be the largest biotech IPO since 2024, overtaking Aktis Oncology’s $318 million offering last month.

The California-based company has already set out its plans for spending the proceeds, with the biggest priority labeled as the clinical development of EIK1001. The toll-like receptor 7 and 8 agonist immune modulator, which Eikon acquired from Seven and Eight Biopharmaceuticals, is currently being tested in a phase 2/3 trial in combination with Keytruda for advanced melanoma and a phase 2/3 study for non-small cell lung cancer.

Behind EIK1001 is a pair of PARP1 inhibitors, dubbed EIK1003 and EIK1004, which Eikon licensed from Chinese biotech Impact Therapeutics. These candidates are being trialed in phase 1/2 studies for ovarian, breast, prostate and pancreatic cancers, with EIK1004 also being assessed against brain metastases and primary brain malignancies due to its ability to cross the blood-brain barrier.

The fourth clinical candidate is an in-house WRN helicase inhibitor called EIK1005, which is in phase 1/2 development for solid tumors.

Galaxy Digital (GLXY) reported earnings on Tue 3 Feb 26 (b/o)

• Galaxy Digital reports fiscal Q4 2025 results with non-GAAP EPS of -$1.08 and revenue of $10.2B, missing estimates; an SEC filing also shows a Q4 net loss of $482M, a full-year 2025 net loss of $241M, and equity capital up 38% to $3.0B as of year-end 2025.